TG THERAPEUTICS ($TGTX) posted quarterly earnings results on Monday, August 4th. The company reported earnings of $0.17 per share, missing estimates of $0.22 by $0.05. The company also reported revenue of $141,150,000, missing estimates of $150,328,038 by $-9,178,038.
You can see Quiver Quantitative's $TGTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TG THERAPEUTICS Insider Trading Activity
TG THERAPEUTICS insiders have traded $TGTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- YANN ECHELARD sold 10,000 shares for an estimated $369,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TG THERAPEUTICS Hedge Fund Activity
We have seen 183 institutional investors add shares of TG THERAPEUTICS stock to their portfolio, and 163 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP removed 1,766,009 shares (-19.2%) from their portfolio in Q1 2025, for an estimated $69,633,734
- OPALEYE MANAGEMENT INC. removed 1,725,000 shares (-76.3%) from their portfolio in Q1 2025, for an estimated $68,016,750
- WELLINGTON MANAGEMENT GROUP LLP added 1,149,526 shares (+1809.9%) to their portfolio in Q1 2025, for an estimated $45,325,810
- CLEARBRIDGE INVESTMENTS, LLC added 809,330 shares (+44.1%) to their portfolio in Q1 2025, for an estimated $31,911,881
- DRIEHAUS CAPITAL MANAGEMENT LLC added 774,656 shares (+inf%) to their portfolio in Q1 2025, for an estimated $30,544,686
- FMR LLC added 711,935 shares (+69.0%) to their portfolio in Q1 2025, for an estimated $28,071,597
- WOODLINE PARTNERS LP added 533,134 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,021,473
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TG THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 03/04/2025
To track analyst ratings and price targets for TG THERAPEUTICS, check out Quiver Quantitative's $TGTX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
